TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3492413
Drug: Sucralfate 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate 1.0 g qid
Study: 3492413
Drug: Aspirin 2.5
Normalized name: aspirin 2.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 2.5 g
Study: 30467685
Drug: Combined spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined spironolactone (25 mg/d) plus vitamin E (400 IU/d) for 52 weeks
Study: 27639137
Drug: Extended-release naproxen
Normalized name: naproxen Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release naproxen sodium 660 mg once daily
Study: 27639137
Drug: Immediate-release naproxen
Normalized name: naproxen Delayed Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release naproxen sodium 220 mg twice daily (440 mg initially, followed by 220 mg 12 hours later)
Study: 18363528
Drug: Medication reconciliation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication reconciliation program (113 patients)
Study: 15821181
Drug: Soy oil
Normalized name: Hydrogenated soy oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy oil (2 g/d)
Study: 10716040
Drug: Phenylpropanolamine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylpropanolamine administered in combination with chlorpheniramine maleate at 2200 hours
Study: 10716040
Drug: Phenylpropanolamine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phenylpropanolamine administered in combination with chlorpheniramine maleate at 1000 hours
Study: 8538480
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg oestradiol valerate (days 1‐21) + 1 mg cyproterone acetate (days 12‐21)
Study: 8538480
Drug: Transdermal 17
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal 17 beta‐oestradiol (50 micrograms twice weekly during three weeks) + 20 mg dydrogesterone (days 12‐21)
Study: 7368149
Drug: Subcutaneous calcium
Normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous calcium heparin (2,500 u pre‐operatively then 5,000 u 12‐hourly for 7 days)
Study: 31989330
Drug: Newly developed
Normalized name: petrolatum
DrugBank: Petrolatum (DB11058)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Newly developed extended-release HPMC niacin formulation
Study: 31989330
Drug: Originator extended-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Originator extended-release niacin product
Study: 30297210
Drug: Naftazone 160
Normalized name: Naftazone
DrugBank: Naftazone (DB13680)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naftazone 160 mg/day
Study: 28662378
Drug: Flexible lightwand
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flexible lightwand (Group L)
Study: 26795957
Drug: Standardized oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized oral health program once yearly between 1 and 3 years of age (Control)
Study: 24115314
Drug: Bolus calculator
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus calculator and wireless communication between insulin pump and blood glucose metre (Group A)
Study: 24115314
Drug: Post-prandial glycaemia,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-prandial glycaemia, body mass index-SD score, insulin/kg/24 h (Group A)
Study: 21499896
Drug: Patupilone combined
Normalized name: Patupilone
DrugBank: Patupilone (DB03010)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patupilone combined with midazolam 4 mg PO (days 1 and 29)
Study: 21499896
Drug: Patupilone combined
Normalized name: Patupilone
DrugBank: Patupilone (DB03010)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patupilone combined with omeprazole 40 mg PO (days 1 and 29)
Study: 19700170
Drug: Class III
Normalized name: HLA class III antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Class III antiarrhythmic drugs (AADs)
Study: 19700170
Drug: Not taking
Normalized name: Lamictal 25mg-100mg Tablet Starter Kit (For Patients Not Taking Enzyme-Inducing Drugs or Valproate)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Not taking class III antiarrhythmic drugs (AADs)
Study: 17915799
Drug: Sodium feredetate
Normalized name: Sodium feredetate
DrugBank: Sodium feredetate (DB13381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium feredetate (33 mg elemental iron) with vitamin B12 (15 microg) and folic acid (1.5 mg) administered twice a day (Group A)
Study: 17915799
Drug: Sodium feredetate
Normalized name: Sodium feredetate
DrugBank: Sodium feredetate (DB13381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sodium feredetate (66 mg elemental iron) with vitamin B12 (15 microg) and folic acid (1.5 mg) administered twice a day (Group B)
Study: 17915799
Drug: Ferrous fumarate
Normalized name: Ferrous Fumarate
DrugBank: Ferrous fumarate (DB14491)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ferrous fumarate (100 mg elemental iron) with vitamin B12 (15 microg) and folic acid (1.5 mg) administered twice a day (Group C)
Study: 15205383
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral dose of [(14)C]capravirine (1400 mg)
Study: 15205383
Drug: Multiple oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple oral doses of ritonavir (100 mg) followed by a single oral dose of [(14)C]capravirine (1400 mg)
Study: 9222182
Drug: OPC-14117 240
Normalized name: OPC-14523
DrugBank: OPC-14523 (DB05422)
Approvals — FDA: no, EMA: no, PMDA: no
Description: OPC-14117 240 mg per day
Study: 3662059
Drug: LE +
Normalized name: Perle +
Approvals — FDA: no, EMA: no, PMDA: no
Description: LE + NaHCO3 (0.1 mEq/ml anesthetic solution)
Study: 29766318
Drug: Sildenafil citrate
Normalized name: Sildenafil Citrate
DrugBank: Sildenafil (DB00203)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sildenafil citrate 50 mg tablet once daily
Study: 16192545
Drug: CSE using
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSE using bupivacaine 0.5% for spinal anesthesia and ropivacaine 0.2% with 0.5 microg/mL of sufentanil for postoperative epidural analgesia (CSE; n = 8)
Study: 8608877
Drug: Mesalamine (Pentasa)
Normalized name: Mesalamine
DrugBank: Mesalazine (DB00244)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mesalamine (Pentasa) 4 g . day(‐1)
Study: 6604081
Drug: Dazoxiben (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dazoxiben (100 mg orally three times once every 4 hr)
Study: 27574399
Drug: FDC therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDC therapy (40 mg olmesartan medoxomil, 20 mg rosuvastatin)
Study: 27574399
Drug: olmesartan medoxomil
Normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: olmesartan medoxomil (40 mg)
Study: 27574399
Drug: rosuvastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosuvastatin (20 mg)
Study: 25048851
Drug: Fosfomycin (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fosfomycin (2 g/6 hours IV) plus Imipenem (1 g/6 hours IV)
Study: 11354529
Drug: Nandrolone decanoate
Normalized name: Nandrolone Decanoate
DrugBank: Nandrolone decanoate (DB08804)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nandrolone decanoate (200 mg per week)
Study: 8028614
Drug: Megestrol acetate
Normalized name: Megestrol Acetate
DrugBank: Megestrol (DB19378)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Megestrol acetate (20 mg twice daily for four weeks)
Study: 2733080
Drug: 200 ml
Normalized name: Bag Top-Fill, 1200 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 ml of a 10% glucose polymer solution at 20 min intervals during exercise (CHO)
Study: 1221326
Drug: 5-drug therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-drug therapy (5 FU, methotrexate, vincristine, cyclophosphamide, and prednisone)
Study: 1221326
Drug: 4-drug therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-drug therapy (5 FU, methotrexate, vincristine, cyclophosphamide)
Study: 1221326
Drug: 5-drug therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-drug therapy
Study: 1221326
Drug: 4-drug therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4-drug therapy
Study: 24644541
Drug: Weekly vitamin
Normalized name: Ezy Dose Weekly Vitamin Planner 2XL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly vitamin D supplementation (cholecalciferol; 50,000 units for 12 weeks)
Study: 20510665
Drug: Prenatal exposure
Normalized name: Ardisia crenata root extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prenatal exposure to beta-blocking agents
Study: 20510665
Drug: Iron supplementation,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplementation, antiemetics, analgesics, antibiotics, or any other main ATC group
Study: 16707912
Drug: Insulin infusion
Normalized name: iLet Insulin Infusion 10-Pack Kit Inset
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin infusion (433 +/- 40 pmol/l)
Study: 16707912
Drug: No insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No insulin (serum insulin levels suppressed at 14 +/- 1 pmol/l)
Study: 14629524
Drug: 1 mL
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mL 25% sucrose
Study: 14629524
Drug: 1 mL
Normalized name: ethanol 1 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mL water (placebo)
Study: 10797125
Drug: Progestin-only oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Progestin-only oral contraceptive (OC P)
Study: 31258136
Drug: 14-day bismuth-containing
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-day bismuth-containing quadruple therapy (BQT)
Study: 31258136
Drug: 10-day moxifloxacin-bismuth-combined
Normalized name: bismuth preparations, combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10-day moxifloxacin-bismuth-combined treatment (MBCT)
Study: 31258136
Drug: 14-day moxifloxacin-bismuth-combined
Normalized name: bismuth preparations, combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14-day moxifloxacin-bismuth-combined treatment (MBCT)
Study: 27432383
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy with vonoprazan-amoxicillin-clarithromycin
Study: 27432383
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy with vonoprazan-amoxicillin-metronidazole
Study: 27432383
Drug: Control (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (single therapy)
Study: 22892157
Drug: ERN (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: ERN (2 g/day)
Study: 22892157
Drug: P‐OM3 (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: P‐OM3 (4 g/day)
Study: 22892157
Drug: Combination treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination treatment (ERN + P‐OM3)
Study: 20462054
Drug: Shenqi Fuzheng
Approvals — FDA: no, EMA: no, PMDA: no
Description: Shenqi Fuzheng Injection (SFI) plus chemotherapy
Study: 18260838
Drug: Indapamide retard
Normalized name: Indapamide
DrugBank: Indapamide (DB00808)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Indapamide retard 1.5 mg
Study: 15778862
Drug: Doxycycline (twice-daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline (twice-daily for 7 days)
Study: 11835022
Drug: Warfarin in
Normalized name: warfarin Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin in addition to aspirin
Study: 2087820
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg ranitidine given after an early evening meal (6 p.m.)
Study: 2087820
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg ranitidine given at bedtime (10 p.m.)
Study: 2087820
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg ranitidine (early evening) for patients with ulcer diameter 5 mm to 9.5 mm and a history of duodenal ulcer
Study: 467056
Drug: Conventional tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional tablet of oral contraceptive
Study: 23541061
Drug: CGS impregnated
Approvals — FDA: no, EMA: no, PMDA: no
Description: CGS impregnated with bFGF at 7 or 14 μg/cm(2) after debridement
Study: 23541061
Drug: CGS impregnated
Approvals — FDA: no, EMA: no, PMDA: no
Description: CGS impregnated with bFGF (low-dose group)
Study: 23541061
Drug: CGS impregnated
Approvals — FDA: no, EMA: no, PMDA: no
Description: CGS impregnated with bFGF (high-dose group)
Study: 22128425
Drug: Acupuncture after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture after administration of aspirin 500 mg
Study: 22128425
Drug: Acupuncture after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture after administration of placebo
Study: 15051597
Drug: 0.7 g
Normalized name: Bioflavonoid 700 MG/0.7 GM Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.7 g DHA/d for 3 months
Study: 26933803
Drug: D-serine administration
Normalized name: D-Serine
DrugBank: D-Serine (DB03929)
Approvals — FDA: no, EMA: no, PMDA: no
Description: D-serine administration
Study: 22801200
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no pulmonary surfactant treatment)
Study: 20536474
Drug: Barrier cream
Normalized name: Ceramax Skin Barrier Cream
DrugBank: Zinc oxide (DB09321)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Barrier cream application alone
Study: 9538713
Drug: Fan therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fan therapy directed to the head
Study: 17999708
Drug: Droperidol (0.625
Approvals — FDA: no, EMA: no, PMDA: no
Description: Droperidol (0.625 mg)
Study: 16831962
Drug: Transdermal estradiol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal estradiol, 0.014 mg/d (n = 208)
Study: 12716083
Drug: Intraperitoneal bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal bupivacaine (0.5%); administered at different times: before dissection, after dissection, or both.
Study: 12716083
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (normal saline); no bupivacaine administered.
Study: 21443793
Drug: 540,000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 540,000 IU (corresponding to 13.5 mg) of cholecalciferol (VITD) dissolved in 45 ml herbal oil
Study: 18595013
Drug: Oral pouch
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral pouch with preserved duodenal passage
Study: 15777293
Drug: Lidocaine spray
Normalized name: lidocaine Mucosal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine spray (40 mg)
Study: 12080833
Drug: Phenytoin and
Normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenytoin and Chinese traditional drug-Jiegudan
Study: 1911606
Drug: TRH administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: TRH administered by a nasal spray of 1 mg, four times daily, for 10 consecutive days starting on day 6 postpartum
Study: 27775195
Drug: Vaginal progesterone
Normalized name: progesterone Vaginal Insert
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaginal progesterone suppositories (400 mg daily)
Study: 27775195
Drug: 17-alpha-hydroxyprogesterone caproate
Normalized name: 17-alpha-hydroxyprogesterone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17-alpha-hydroxyprogesterone caproate (17OHP-C) (250 mg i.m. once a week)
Study: 25995057
Drug: Integrated multi-element
Normalized name: Parasedge Multi
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated multi-element psychosocial intervention (cognitive behavioral therapy, family intervention, and case management)
Study: 21755338
Drug: Continuation of
Normalized name: varenicline
DrugBank: Varenicline (DB01273)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuation of clomiphene citrate (CC)
Study: 17727573
Drug: Antidiuresis treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidiuresis treatment
Study: 15118640
Drug: Hormone Replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone Replacement Therapy (HRT) < 5 years
Study: 15118640
Drug: Hormone Replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone Replacement Therapy (HRT) > or =5 years
Study: 9393428
Drug: Dental implants
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dental implants not coated with hydroxyapatite
Study: 9393428
Drug: Dental implants
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dental implants placed in the maxilla
Study: 9393428
Drug: Dental implants
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dental implants placed in anterior regions of the jaws
Study: 9393428
Drug: Dental implants
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dental implants in completely edentulous cases
Study: 9393428
Drug: Dental implants
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dental implants placed in bone scored as having lower quality
Study: 28572749
Drug: Pomegranate extract
Normalized name: Pomegranate Extract
DrugBank: Pomegranate (DB14317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomegranate extract (POMx) 1000 mg
Study: 26176805
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate (CC) 25 mg/day for 12 weeks
Study: 26176805
Drug: Anastrozole (AZ)
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anastrozole (AZ) 1 mg/day for 12 weeks
Study: 23957734
Drug: Active mesalazine
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active mesalazine 1.6 g/day plus Lactobacillus casei subsp. DG placebo (Group M)
Study: 23957734
Drug: Active Lactobacillus
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active Lactobacillus casei subsp. DG 24 billion/day plus mesalazine placebo (Group L)
Study: 23957734
Drug: Group L
Normalized name: Blood group Lewis alpha-4-fucosyltransferase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group L (placebo)
Study: 22012522
Drug: Risedronate 35
Normalized name: risedronate 35 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risedronate 35 mg orally once weekly for six months
Study: 12859312
Drug: NonACEI treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: NonACEI treatment (Control)
Study: 6310464
Drug: Cefotaxime sodium
Normalized name: Cefotaxime Sodium
DrugBank: Cefotaxime (DB00493)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefotaxime sodium at a dose of 6 g/day
Study: 6310464
Drug: Cefotaxime sodium
Normalized name: Cefotaxime Sodium
DrugBank: Cefotaxime (DB00493)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefotaxime sodium at a dose of 3 g/day
Study: 31280535
Drug: Sling Treatment
Normalized name: Sling Small/Medium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sling Treatment (ST)
Study: 21803872
Drug: American ginseng
Normalized name: American ginseng
DrugBank: Panax quinquefolius whole (DB14296)
Approvals — FDA: no, EMA: no, PMDA: no
Description: American ginseng (100 mg, 200 mg, 400 mg/day)
Study: 16952819
Drug: 20 mL
Normalized name: Exact-Med, 20 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mL ropivacaine 0.5%
Study: 16952819
Drug: 30 mL
Normalized name: Vial M/T 30 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mL ropivacaine 0.5%
Study: 16952819
Drug: 40 mL
Normalized name: hydrogen peroxide 40 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mL ropivacaine 0.5%
Study: 27761966
Drug: Occupational Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occupational Therapy Task-Oriented (TO) intervention for 6 weeks, 3 hours per week
Study: 24097288
Drug: Low-dose aspirin
Normalized name: low-dose aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-dose aspirin plus low-intensity warfarin (LDA + W)
Study: 24160231
Drug: Diet with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diet with daily supplementation of 10,000 IU of vitamin A, 400 mg of vitamin E, and 600 mg of vitamin C (G2)
Study: 21923449
Drug: Metoprolol ER
Normalized name: Hydrochlorothiazide-Metoprolol ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol ER 100 mg with paroxetine
Study: 21923449
Drug: Metoprolol ER
Normalized name: Hydrochlorothiazide-Metoprolol ER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol ER 200 mg with paroxetine
Study: 21923449
Drug: Metoprolol IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol IR (two 100 mg doses) with paroxetine
Study: 18312046
Drug: LETS Act!
Approvals — FDA: no, EMA: no, PMDA: no
Description: LETS Act! (brief behavioral therapy for depression)
Study: 16597655
Drug: Saline 2
Normalized name: SODIUM CHLORIDE BRONCHO-SALINE 240ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline 2 ml (control group)
Study: 11079089
Drug: GPW mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: GPW mixture (gelatin, Peritrast, and water) administered over an intestinal tube
Study: 8837238
Drug: 3.75 mg
Normalized name: zopiclone 3.75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3.75 mg leuprolide depot intramuscularly every 28 days for 24 weeks
Study: 20032953
Drug: Cereton (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cereton (1000 mg)
Study: 20032953
Drug: Piracetam (2000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piracetam (2000 mg)
Study: 16762944
Drug: Phenylalanine intake
Normalized name: Phenylalanine
DrugBank: Phenylalanine (DB00120)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenylalanine intake of 38 mg . kg(‐1) . d(‐1)
Study: 16762944
Drug: Phenylalanine intake
Normalized name: Phenylalanine
DrugBank: Phenylalanine (DB00120)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Phenylalanine intake of 37 mg . kg(‐1) . d(‐1)
Study: 8665998
Drug: Conventional rapid
Normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional rapid release preparation of oxipurinol sodium
Study: 2218006
Drug: Enprofylline 150
Normalized name: Enprofylline
DrugBank: Enprofylline (DB00824)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enprofylline 150 mg bd for 2 weeks, then 300 mg bd for 3 weeks
Study: 2218006
Drug: Theophylline 150
Normalized name: theophylline 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline 150 mg bd for 2 weeks, then 300 mg bd for 3 weeks
Study: 29650037
Drug: Experimental schedule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental schedule 2/1 (50 mg daily)